Curis stock has recently drawn increased attention following the latest round of analyst updates, with the consensus price target holding steady at $14.00 per share. While forecasts show little ...
The list of biotechs under clinical hold keeps getting longer. Curis is the latest company to join the list, with the FDA slapping a partial hold on a phase 1/2a leukemia study while it gathers ...
Curis (CRIS 1.98%), a small-cap cancer specialist, posted a healthy gain in August. The biotech's shares rose by 16.6% last month, according to data provided by S&P Global Market Intelligence. What ...
Zacks Investment Research on MSN
Curis (CRIS) upgraded to buy: What does it mean for the stock?
Investors might want to bet on Curis (CRIS), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most ...
LEXINGTON, Mass., July 2, 2025 /PRNewswire/ -- Curis, Inc. (CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, ...
Cancer drug specialist Curis (NASDAQ: CRIS) had a Friday to forget. The biotech's share price took a nearly 37% hit after the company reported some disquieting news about a leading pipeline drug.
CAMBRIDGE, Mass., Feb 12, 2010 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS), announced today that its licensee Debiopharm S.A. ("Debiopharm") has received approval from France's regulatory authority ...
What a difference a day makes. Following a serious pop for its stock on Wednesday, given very encouraging news about one of its pipeline drugs, Curis (NASDAQ: CRIS) saw its shares dive by almost 20% ...
LEXINGTON, Mass., April 19, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, is pleased to ...
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Curis is back on investors’ radar after analysts reaffirmed a US$14.00 fair value per ...
- Dr. Voi brings over 20 years of broad industry experience including development of XALKORI® (crizotinib), Erbitux® (cetuximab), Sprycel® (dasatinib) and Gemzar® (gemcitabine for injection) - ...
LEXINGTON, Mass., Oct. 29, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results